Journal
JOURNAL OF NEUROINFLAMMATION
Volume 13, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s12974-016-0566-y
Keywords
IL-25; Type 2 immune response; Spinal cord injury; Basso mouse scale; Locomotor recovery; Th1; Th2
Categories
Funding
- Research Foundation Flanders (FWO Vlaanderen) [1.2.703.10N, 1.2.703.13N, G.0834.11N, G.0389.12, G.0A5813, G.0A14.13]
Ask authors/readers for more resources
Background: The cytokine, interleukin (IL)-25, is thought to be critically involved in inducing a type 2 immune response which may contribute to regeneration after central nervous system (CNS) trauma. We investigated whether applying recombinant IL-25, locally or systemically, in a mouse model of spinal cord injury (SCI) improves functional and histological recovery. Findings: Repeated systemic administration of IL-25 did not influence functional recovery following SCI. In contrast, a single local administration of IL-25 significantly worsened locomotor outcome, which was evident from a decreased Basso mouse scale (BMS) score compared with phosphate-buffered saline (PBS)-treated controls. This was accompanied by a significant increase in lesion size, demyelination, and T helper cell infiltration. Conclusions: These data show for the first time that IL-25 is either ineffective when applied systemically or detrimental to spinal cord recovery when applied locally. Our findings question the potential neuroprotective role of IL-25 following CNS trauma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available